DASHENLIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.2 CNY | +2.27% |
|
-5.02% | -14.86% |
| 28/04 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 18/03 | Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares | MT |
Evolution of the average Target Price on DaShenLin Pharmaceutical Group Co., Ltd.
Price target over the last 5 years
History of analyst recommendation changes
e7948180c8d9015cebeec40a3db8.u1xqamlAgytJgkhcKkbXo4wX3HBeiKTxy-AoaSm9sx4.zjYfITsJ8mYw5jgSEnS5l_4khUAcwPzBgtkbO0Ta6nrIbl4GKzfZHQ7gJw~e7f6a9a80a236af90be668f028efa373
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.2
CNY
Average target price
33.62
CNY
Spread / Average Target
+58.61%
High Price Target
38
CNY
Spread / Highest target
+79.25%
Low Price Target
28.9
CNY
Spread / Lowest Target
+36.32%
Consensus detail
Consensus revision (last 18 months)
Analysts covering DaShenLin Pharmaceutical Group Co., Ltd.
| UBS |
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
- Stock Market
- Equities
- 603233 Stock
- Consensus DaShenLin Pharmaceutical Group Co., Ltd.
